World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
42919
World Ranking
5353
National Ranking
297

Overview

Kristian Reich is a researcher affiliated with the University of Göttingen in Germany. Their work primarily focuses on the fields of medicine, immunology, and dermatology, with a research portfolio that bridges immunology and microbiology. Reich's subfields include immunology, immunology and allergy, dermatology, rheumatology, and physiology.

The research topics they address cover a broad spectrum related to skin and immune system diseases, particularly:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Asthma and respiratory diseases
  • Autoimmune Bullous Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical studies and practices

Kristian Reich has published extensively, with a significant number of works appearing in highly regarded dermatology and medical journals. Frequent publication venues include:

  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology
  • Journal of the European Academy of Dermatology and Venereology
  • SKIN The Journal of Cutaneous Medicine
  • Journal of Investigative Dermatology

The scientist has collaborated regularly with other prominent researchers in the field. Frequent co-authors include:

  • Andrew Blauvelt
  • Richard G. Langley
  • Richard B. Warren
  • Mark Lebwohl
  • Matthias Augustin

Among Kristian Reich's recent publications are several notable papers such as:

  • Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021, The Lancet)
  • Bimekizumab versus Secukinumab in Plaque Psoriasis (2021, New England Journal of Medicine)
  • Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021, The Lancet)

These publications focus on clinical trials and therapeutic advancements targeting skin conditions such as atopic dermatitis and plaque psoriasis. The work involves randomized controlled studies assessing safety and efficacy of novel treatments.

Best Publications

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial

    Kristian Reich;Frank O Nestle;Kim Papp;Jean-Paul Ortonne

  • Definition of treatment goals for moderate to severe psoriasis: a European consensus

    U. Mrowietz;K. Kragballe;K. Reich;P. Spuls

  • European S3-guidelines on the systemic treatment of psoriasis vulgaris

    D Pathirana;AD Ormerod;P Saiag;Catherine Smith

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.

    Kristian Reich;April W. Armstrong;Peter Foley;Michael Song

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Diamant Thaçi;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai

  • Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Kristian Reich;Kim A Papp;Andrew Blauvelt;Stephen K Tyring

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Epidemiology and comorbidity of psoriasis in children

    M. Augustin;G. Glaeske;M.A. Radtke;E. Christophers

  • Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

    M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  • European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

    A Nast;P Gisondi;A D Ormerod;P Saiag

  • Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

    K A Papp;C E M Griffiths;K Gordon;M Lebwohl

  • Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

    K. Reich;K. Krüger;R. Mössner;M. Augustin

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

    Marcus Maurer;Sabine Altrichter;Thomas Bieber;Tilo Biedermann

  • S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

    Alexander Nast;Wolf-Henning Boehncke;Ulrich Mrowietz;Hans-Michael Ockenfels

  • Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany.

    Matthias Augustin;Kristian Reich;Gerd Glaeske;Ines Schaefer

  • A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

    Kenneth B. Gordon;Kristina Callis Duffin;Robert Bissonnette;Jörg C. Prinz

Frequent Co-Authors

Ulrich Mrowietz
Ulrich Mrowietz Kiel University
Matthias Augustin
Matthias Augustin Universität Hamburg
Kim Papp
Kim Papp Probity Medical Research
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Diamant Thaçi
Diamant Thaçi University of Lübeck
Richard G. Langley
Richard G. Langley Dalhousie University
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées
Craig L. Leonardi
Craig L. Leonardi Saint Louis University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering alternative routes into healthcare, pursuing online degrees can be a flexible and cost-effective solution. Whether you’re looking at entry-level roles or aiming for advanced practice, there are a wide range of programs available online.

If administrative healthcare appeals to you, medical coding certification cost is an important factor to consider. Acquiring certification online is often more affordable than in-person options, making it accessible to more students.

For those seeking clinical careers, exploring the how much is online nursing school question is crucial. Many online nursing programs provide flexible schedules without the high price tag of on-campus learning.

Aspiring nurse practitioners can compare the cheapest fnp programs to find affordable pathways to become a Family Nurse Practitioner, a highly respected role in the medical field.

For those interested in leadership or academia, pursuing phd nursing education online allows for advancing your credentials while maintaining work-life balance.

Best Scientists Citing Kristian Reich

Trending Scientists